84.17MMarket Cap-625P/E (TTM)
0.820High0.750Low1.14MVolume0.750Open0.761Pre Close903.90KTurnover1.14%Turnover RatioLossP/E (Static)108.57MShares3.33052wk High6.01P/B77.63MFloat Cap0.67252wk Low--Dividend TTM100.14MShs Float35.200Historical High--Div YieldTTM9.19%Amplitude0.672Historical Low0.789Avg Price1Lot Size
Gritstone Bio Stock Forum
NEWS
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
NEWS
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE --
-- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. ...
No comment yet